Stoll, Sharon
Costello, Kathleen
Newsome, Scott D.
Schmidt, Hollie
Sullivan, Amy B.
Hendin, Barry
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 6 September 2023
Accepted: 7 December 2023
First Online: 5 January 2024
Declarations
:
: Sharon Stoll has served on scientific advisory boards for Bristol Myers Squibb, F. Hoffmann-La Roche Ltd., Genentech, Forepont Capital Partners, Horizon, and TG Therapeutics; received research support from BeCare MS Link and MedDay Pharmaceuticals; received compensation for consulting services, served on scientific advisory boards, and received speaker honoraria for Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Horizon, Novartis, Roche/Genentech, and Sanofi/Genzyme; is CEO of Global Consultant MD; and serves on the steering committee of Horizon and Roche/Genentech. Kathleen Costello has served on advisory boards for Bristol Myers Squibb, Genentech, Novartis, and Sanofi. Can Do MS has received support from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Novartis, Sanofi, Sandoz, TG Therapeutics, and Viatris. Scott D. Newsome reports consultant fees for scientific advisory boards from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Greenwich Biosciences, Horizon Therapeutics, Novartis, and TG Therapeutics; is an adviser for Autobahn; is the study lead principal investigator for a Roche clinical trial; was a clinical trial adjudication committee member for MedDay Pharmaceuticals; and has received research funding (paid directly to institution) from Biogen, Genentech, National Multiple Sclerosis Society (NMSS), Patient-Centered Outcomes Research Institute (PCORI), Roche, Stiff Person Syndrome Research Foundation, and US Department of Defense. Hollie Schmidt works for the Accelerated Cure Project for MS (ACP), which has received grants, collaboration funding, payments for use of assets, or in-kind contributions from the following companies: AbbVie, AstraZeneca, BC Platforms, Biogen, Bristol Myers Squibb, Celgene, EMD Serono, Genentech, GlycoMinds, Mallinckrodt, MedDay Pharmaceuticals, MSDx, Novartis, Octave, Pfizer, Regeneron Genetics Center, Sandoz, Sanofi/Genzyme, and Teva. ACP has also received funding from PCORI and NMSS. Amy B. Sullivan has served as a consultant and speaker for Biogen, Bristol Myers Squibb, EMD Serono, Genentech, and Novartis. Barry Hendin has received research, advisory, or speaker’s bureau support from Alexion, Biogen, EMD Serono, Genentech, Genzyme, Horizon, and Novartis.
: This article does not contain any new studies with human participants or animals performed by any of the authors.